Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by pattyb77on May 30, 2019 12:44am

152 Views

Post# 29783996

RE:Gap up tomorrow 🚀🚀🚀

Now now guys, lets not get carried away. Yes we are breaking downtrend but there are multiple resistances to pass before we even high teens again. Gap up is very unlikely as KLY doesn't gap up at these lvls. Only time I would see KLY gap up is on some kind of partnership news pre market with a halt.... regardless, Momentum is good right now and I think baby steps is key to keep consistent upward pressure. Also, KLY likes to do these 'random' run ups, technicals have been suggesting its been due for one (based on historic chart patterns) so I dont want to create a false optimism until it can pass those resistance lvls. Im looking at $0.10 to be the first big resistance to pass. Anyways just my opinion. Good luck

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide